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Abstract
Background While generic health status measures quan-
tify the impact of all patients’ diseases on their health-
related quality of life, disease speciﬁc measures focus on
only one of the many conditions that a patient may have. If a
patienthastwodiseaseswith similarclinicalmanifestations,
they may respond differently to a disease-speciﬁc instru-
ment if one of their conditions improves while the other
worsensorremainsstable,thusunderminingtheinstruments
in that patient population. We sought empirical evidence of
the reliability and validity (including responsiveness) of the
Kansas City Cardiomyopathy Questionnaire (KCCQ), a
disease-speciﬁc measure for heart failure (HF), among HF
patients with and without anemia, a condition that has
similar symptoms to HF.
Methods This work used a prospective cohort study of
811 HF outpatients from 58 U.S. centers with a baseline
assessment of anemia of whom 698 were followed for
3 months with serial health status measures.
Results Among participants, 268 (33%) were anemic.
The construct validity of the KCCQ was supported by
showing similar correlations with the New York Heart
Association (NYHA) classiﬁcation in patients with and
without anemia (P value for interaction = 0.38). The
internal consistency (Cronbach’s alpha = 0.92 and 0.93 for
anemic and non-anemic patients, respectively) and test–
retest reliability (mean 3-month change scores in stable
patients =- 2.8 [SD = 1.4] and -0.5 [SD = 0.8],
P = 0.14) were similar. Estimates of responsiveness were
also similar.
Conclusion This study provides empirical evidence that
the psychometric properties of the KCCQ are similar in
patients with or without anemia, a potentially confounding
clinical condition in patients with heart failure.
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Abbreviations
GFR Glomerular ﬁltration rate
HF Heart failure
KCCQ Kansas City Cardiomyopathy Questionnaire
and its overall summary score
NYHA New York Heart Association
STAMINA-
HFP
STudy of AneMia IN A Heart Failure
Population
WHO World Health Organization
Introduction
The quantiﬁcation of patients’ health status (their symp-
toms, function, and health-related quality of life) is
becoming increasingly important as an endpoint in clinical
trials [1, 2], as a means of monitoring patients over time
[3], and even as a marker of health care quality [4–6].
Measuring patients’ health status is most commonly
accomplished by direct solicitation from patients them-
selves, using either generic or disease-speciﬁc health status
questionnaires [7]. Whereas generic health status measures
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of patients’ ‘overall health’, including all combinations of
diseases and ailments, disease-speciﬁc measures focus
upon a speciﬁc disease process. Accordingly, an advantage
of disease-speciﬁc questionnaires is that they can be both
more sensitive to clinical change and more interpretable
than general health status questionnaires. Because disease-
speciﬁc instruments tend to be more actionable to clini-
cians, they can be useful in monitoring patients’ clinical
status over time [8]. An unresolved challenge in the use of
disease-speciﬁc measures, however, is whether they per-
form well when patients have other conditions that may also
impact their symptoms, function, and quality of life in ways
that are similar to the speciﬁc disease of interest. While this
is not a problem with generic health status measures, if a co-
occurring disease manifests similar effects to a primary
disease of interest, and if one of the conditions worsens
while the other remains stable or improves, then it is
unknown whether the disease-speciﬁc measure will accu-
rately measure the status of the disease it is designed to
quantify. This can undermine the original validity, reli-
ability and responsiveness of the disease-speciﬁc measure.
One potential setting in which this type of confounding may
occur is in the setting of heart failure and anemia.
Heart failure (HF) affects over 5 million Americans and
is responsible for enormous health care costs and resource
utilization [9]. While several disease-speciﬁc measures for
patients with HF have been created to quantify HF patients’
health status [10–13], the psychometric properties of these
instruments have all been demonstrated in patients whose
predominant medical condition was heart failure. Recently,
however, anemia has emerged as an important co-occurring
condition that is prognostically important in HF [14–21].
Importantly, the symptoms of anemia may mimic those of
HF. Speciﬁcally, chronic anemia manifests itself in patients
as ‘‘fatigue, loss of stamina, breathlessness, and tachycar-
dia, particularly with exertion’’ [22], coupled with the
development of ‘‘gradual fatigue and a reduced exercise
tolerance’’ [23]. The symptoms of anemia [24] are there-
fore remarkably similar to those of HF, for which
breathlessness, reduced exercise tolerance, and fatigue are
hallmarks of the disease [22, 23]. Because of the overlap in
symptomatic manifestations of both diseases, it is not clear
whether heart failure-speciﬁc health status assessments,
such as the Kansas City Cardiomyopathy Questionnaire
(KCCQ) which captures patients’ perspectives of their
disease rather than physiologic or anatomic characteristics
(e.g. their hematorit or left ventricular function), would
perform similarly in patients with and without anemia. For
example, if a patient’s heart failure symptoms improve
from an increased use of diuretics, would there be an
improvement in their KCCQ scores if their anemia did not
change? Consequently, it is unknown whether the
psychometric properties of a disease-speciﬁc HF instru-
ment would be similar in anemic and nonanemic HF
patients, given the potential for both conditions to induce
similar symptoms in patients. The purpose of this analysis
was to provide empirical evidence supporting the reliability
and validity (including responsiveness) of the KCCQ in
anemic HF patients. We sought to compare the psycho-
metric properties, including reliability (internal consistency
and test–retest) and validity (including responsiveness to
clinical change), in anemic and nonanemic HF patients.
Methods
Patient population
The STudy of AneMia IN A Heart Failure Population
(STAMINA-HFP) was a prospective registry of 1,090 HF
patients who were initially enrolled in the outpatient clinics
of 58 U.S. cardiology centers. The purpose of STAMINA-
HFP was to estimate the incidence and prevalence of
anemia in patients with HF and to describe the association
of anemia with HF progression. As such, the protocol
mandated an initial clinical history and physical exam
(including assignment of the New York Heart Association
[NYHA] classiﬁcation), a measurement of patients’
hemoglobin, and an assessment of their health status,
including the KCCQ. Enrolled patients were contacted by
telephone within 1–2 days after their initial enrollment and
every 3 months for a period of 1 year to assess their health
status. In addition, data from outpatient visits during the
year of observation were abstracted at each visit. To be
eligible for participation, patients had to be [18 years of
age, diagnosed with a history of symptomatic HF and
willing to provide informed consent. Patients who had a
prior organ transplant, were planning a major surgery, or
were participating in another interventional trial were
excluded. Data capture was completed in the STAMINA-
HFP registry in July 2004. Patients participating in this
study (n = 811) had to have complete baseline health
status assessments and a measure of hemoglobin. They
were slightly more likely to be white (75% vs. 68%,
P = 0.03) and to not smoke (90% vs. 86%, P = 0.03) but
had similar distributions of NYHA class, KCCQ scores,
and hemoglobin as compared with the entire cohort of
1,090 patients. For the longitudinal assessments of test–
retest reliability and responsiveness, a 3-month health
status assessment was also required from these patients
(n = 698). At the time of follow-up interviews, a patient
global assessment of change question, asking patients to
describe ‘how [they] think [their] condition has changed
compared to the start of the study,’ was also asked at each
follow-up interview. Responses were on a 7-point
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123categorical response scale ranging from ‘markedly
improved’ to ‘markedly worse.’ The initial 3-month
assessment was used for this study because it was the
closest assessment to the time of their anemia evaluation
and because it had the shortest recall period with which to
assess patients’ perspectives of clinical change of any of
the other assessments.
The KCCQ is a 23-item, disease-speciﬁc measure that
quantiﬁes four clinically relevant domains of patients’
health status including physical limitations, symptoms
(frequency, severity, and change over time), a heart failure-
speciﬁc assessment of their quality of life and their per-
ceived social limitations due to heart failure, and a self-
efﬁcacy domain (a measure of patients’ knowledge of how
to best manage their disease). The four health status scales
can be combined into a single, overall summary score [10].
Scores range from 0–100, where higher scores indicate
better functioning, fewer symptoms, and better disease-
speciﬁc quality of life. The KCCQs validity and repro-
ducibility have been previously supported and recent
studies have demonstrated that both cross-sectional varia-
tions [25, 26] and changes [27] in KCCQ scores are
prognostic of subsequent mortality and HF hospitaliza-
tions. A mean difference between groups of patients and an
intra-individual change over time of C5 points is consid-
ered clinically signiﬁcant. This was established in two
studies: a prospective study of 476 outpatients in which a
mean change of ﬁve points in the KCCQ overall summary
scale was observed in those patients who experienced a
small, but clinically signiﬁcant change in their heart failure
[28] and in a prospective study of 1,358 HF patients in
which a 5-point change was associated with an 11% change
in the multivariable-adjusted hazard ratio of hospitalization
and cardiovascular death [27].
Classiﬁcation of anemia
Patients were classiﬁed as being anemic or not based upon
their hemoglobin at the time of study enrollment. Thus, the
patients’ hemoglobin value at baseline determined their
anemia status throughout the remainder of the study. The
World Health Organization (WHO) deﬁnition of anemia
was used (hemoglobin \13 g/dl for men, \12 g/dl for
women).
Statistical analysis
The patient population was divided into those with and
without anemia, and baseline demographic and clinical
characteristics were compared with chi-square tests for
categorical variables and t tests for continuous variables.
To evaluate the construct validity of the KCCQ in
anemic and nonanemic patients, comparisons across
NYHA classiﬁcations from the baseline interviews were
conducted. A two-way ANOVA with KCCQ overall
summary score as the dependent variable and baseline
anemia classiﬁcation, NYHA, and an anemia-by-NYHA
interaction term as independent variables was constructed
to establish whether the association of NYHA and KCCQ
was different in patients with and without anemia.
Both internal consistency and test–retest reliability
estimates were compared among anemic and nonanemic
patients. Internal consistency reliability was estimated
using Cronbach’s alpha. This value was calculated inde-
pendently for patients with and without anemia. Test–retest
reliability was performed using a t test, by comparing the
3-month change in KCCQ scores for patients who
responded on the global change in health question that their
condition was stable over the previous 3 months. Three
months was selected as the interval of analysis to maximize
the number of patients included in the analyses, to leverage
the existing data in which a 3-month interval was selected,
and to replicate the time frame of the original validation
studies evaluating the KCCQ [10].
To compare the responsiveness of the KCCQ in patients
with and without anemia, the association of patients’ means
change in KCCQ scores with their responses to the global
health question were assessed using linear regression. In
these linear regression analyses, the mean change in KCCQ
scores was used as the dependent variable and baseline
anemia status, global assessment of change, and an anemia-
by-global assessment of change interaction term were
independent variables. As a secondary analysis, patients’
perspectives of their 3-month change in status was cate-
gorized into improved (mildly–markedly), stable (no
change), and worsened (mildly–markedly), and mean
change in KCCQ scores were compared for those with and
without anemia by these patient-perceived categories of
change in health status. All analyses were conducted in
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). All
statistical tests were two-sided and a P value \0.05 was
used as the threshold to declare statistical signiﬁcance.
Results
Patient characteristics
Overall, 811 patients completed the baseline clinical
assessments, including the KCCQ interview, and were used
to assess baseline construct validity and internal consis-
tency reliability. Only 4% of the population had KCCQ
scores of 100, suggesting a minimal ceiling effect of the
instrument in this population. Among the patients who
Qual Life Res (2008) 17:291–298 293
123completed the baseline assessments, 268 (33%) met the
WHO criteria for anemia. Baseline characteristics of the
anemic and nonanemic patients are provided in Table 1.
Compared to nonanemic patients, anemic patients were
signiﬁcantly more likely to be older than (mean ± SD =
67 ± 13 vs. 63 ± 14 years, P\0.001), non-Caucasian
(30% vs. 23%, P = 0.03), and to have an ischemic HF
etiology (46% vs. 38%, P = 0.04), diabetes (47% vs. 34%,
P\0.001), lower glomerular ﬁltration rate (GFR)
(50.8 ± 24.6 vs. 63.9 ± 23.1 ml/min/m
2, P\0.001),
chronic renal insufﬁciency (33% vs. 15%, P\0.001),
higher serum creatinine (1.7 ± 1.5 vs. 1.3 ± 1.2 mg/dl,
P\0.001), worse NYHA class (44% vs. 32% class III or
IV, P\0.001), lower KCCQ scores (61 ± 23 vs.
65 ± 23, P = 0.009), and to be treated with diuretics (90%
vs. 84%, P = 0.04).
For the longitudinal analyses of test–retest reliability
and responsiveness, 698 (86.1%) patients provided both
baseline and 3-month assessments. No statistically
signiﬁcant differences in any of the patient characteristics
listed in Table 1 were observed between those who did
and did not participate in the 3-month interviews. Nota-
bly, no difference in anemia classiﬁcation (33.0% among
participants vs. 33.6% in those without follow-up,
P = 0.89) or mean hemoglobin (13.2 ± 1.8 vs.
13.2 ± 2.1, P = 0.94) was observed between those with
and without follow-up.
Construct validity
Figure 1 illustrates the relationship between the overall
KCCQ score by NYHA class in anemic and nonanemic
patients. Mean KCCQ scores tracked strongly with
NYHA class (mean summary score ± SE for the entire
population = 80.3 ± 1.6, 68.0 ± 1.0, 50.9 ± 1.2, and
45.6 ± 5.4 for NYHA classes I–IV respectively,
P\0.0001). While the mean KCCQ scores for the
Table 1 Baseline clinical
characteristics of the population








Age (mean +/- SD) 67.0 +/- 13.1 62.9 +/- 13.5 \0.001
Male (n, %) 105 (39.2%) 239 (44.0%) 0.190
Non-Caucasian (n, %) 80 (29.9%) 123 (22.7%) 0.026
No insurance (n, %) 6 (2.2%) 19 (3.5%) 0.329
Etiology of HF (n, %) 0.038
Hypertensive 49 (18.3%) 92 (17.0%)
Ischemic 124 (46.3%) 208 (38.4%)
Other 95 (35.4%) 242 (44.6%)
Mean left ventricular ejection fraction (mean +/- SD) 36.4 +/- 15.9 35.9 +/- 16.2 0.742
Diabetes (n, %) 125 (46.8%) 185 (34.1%) \0.001
COPD (n, %) 51 (19.1%) 87 (16.0%) 0.273
Chronic renal insufﬁciency (n, %) 89 (33.3%) 82 (15.1%) \0.001
Current smoker (n, %) 17 (6.3%) 61 (11.2%) 0.026
Body mass index (mean +/- SD) 30.3 +/- 7.3 31.1 +/- 7.4 0.181
NYHA (n,% ) 0.001
I 35 (13.1%) 99 (18.2%)
II 116 (43.3%) 268 (49.4%)
III 105 (39.2%) 169 (31.1%)
IV 12 (4.5%) 7 (1.3%)
Mean KCCQ overall summary score (mean +/- SD) 60.8 +/- 22.8 65.3 +/- 23.2 0.009
Current medications (n,% )
ACE inhibitor/ARB 232 (86.6%) 486 (89.5%) 0.217
ß-blocker 222 (82.8%) 446 (82.1%) 0.806
Diuretic 240 (89.6%) 458 (84.3%) 0.044
Spironolactone 76 (28.4%) 132 (24.3%) 0.214
Digoxin 126 (47.0%) 245 (45.1%) 0.610
Mean hemoglobin (mean +/- SD) 11.4 +/- 1.1 14.1 +/- 1.3 \0.001
Mean creatinine (mean +/- SD) 1.7 +/- 1.5 1.3 +/- 1.2 \0.001
Glomerular ﬁltration rate (ml/min/m
2, mean +/- SD)* 50.8 +/- 24.6 63.9 +/- 23.1 \0.001
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123patients with NYHA class IV differed substantially, this
was likely due to the small numbers of patients in these
subgroups, resulting in a large standard deviation of
scores (KCCQ scores in anemic [n = 12] and nonanemic
[n = 7] patients = 39.5 ± 20 vs. 56.2 ± 28). Further-
more, the relationship between KCCQ and NYHA did not
differ signiﬁcantly between anemic and nonanemic
patients (P = 0.38 for interaction).
Reliability
The internal consistency reliability (Cronbach’s alpha) of
the KCCQ overall summary score for the entire population
was 0.93. In patients who were anemic and nonanemic, the
Cronbach alphas were 0.92 and 0.93, respectively.
The mean (±SE) KCCQ overall summary score change
in patients who reported no change over 3 months in their
clinical condition (n = 257) was -1.2 ± 0.7. Among
anemic patients (n = 73) the mean change was -2.8 ± 1.4,
and for nonanemic patients (n = 184) the mean change was
-0.5 ± 0.8. These mean 3-month changes were similar
between anemic and nonanemic patients (P = 0.14).
Importantly, the change between and within both groups
was less than ﬁve points over time and, thus, not considered
clinically signiﬁcant. The intraclass correlation coefﬁcient
for the KCCQ overall summary score was 0.885 in the
overall cohort and did not differ among those with and
without anemia (0.865 for anemic patients and 0.892 for
nonanemic patients [P = 0.11]).
Responsiveness
To compare the sensitivity of the KCCQ to patients’ per-
ceptions ofchange,the mean change inKCCQ scores across
each category of change were compared in anemic and
nonanemic patients. Figure 2 describes the means and 95%
conﬁdence intervals of change in KCCQ scores across crude
categories of improved (mild to marked), no change, and
worsening (mild to marked) of their overall clinical status
during the ﬁrst 3 months of the study. No signiﬁcant
differences by anemia status were detected within any of the
three categories of reported health change. In regression
analysis, mean 3-month KCCQ change was found to be
linearly related to reported health change, with a slope of
-2.7points(95%CI = [-3.6,-1.9])per1stepdownonthe
Likert-scale response. Nonlinearity was tested using cubic
splines and was found to be nonsigniﬁcant (P = 0.68). The
association was consistent in both anemic and nonanemic
patients (slope estimates =- 3.4 [95% CI = (-5.0, -1.8)]
vs. -2.5 [95% CI = (-3.4, -1.6)], P-value = 0.33).
Discussion
We report empirical evidence to support the reliability and
validity (including responsiveness) of the KCCQ in HF
patients with anemia. We found similar associations
between the KCCQ overall summary score and NYHA
classiﬁcation, similar internal consistency and test–retest
reliability in stable patients, and similar responsiveness of
the KCCQ to patients’ perceptions of 3-month clinical
Fig. 1 KCCQ overall summary score by NYHA class in anemic and
nonanemic patients
Fig. 2 Three-month KCCQ change by reported health change and
anemia status
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123change. In light of the potential overlap in symptoms
between anemia and HF, we tested and rejected the
hypothesis that the psychometric properties of the KCCQ
might differ between HF patients with and without anemia.
Thus, the KCCQ could be a valid, reliable, and responsive
outcome for clinical trials of anemia treatment in HF.
To date, there has been a paucity of literature exam-
ining attribution of symptoms to one of a spectrum of
potentially co-occurring diseases in patient-reported
health status assessments. A common recommendation for
the design of clinical trials is to include both disease-
speciﬁc and generic measures of health status. These
recommendations are predicated upon the desire to cap-
ture the impact of treatments on a speciﬁc disease of
interest, as well as the overall impact of treatment on
patients’ health outside the condition of interest. The
latter intended to capture side effects or other unantici-
pated complications of therapy.
However, since patients are often only aware of the
symptoms that they experience, and not the underlying
pathophysiology that is responsible for those symptoms, it
is unclear whether a distinct pathophysiology (e.g. anemia)
could confound the psychometric properties of a disease-
speciﬁc health status measure quantifying a disease with
similar clinical manifestations (e.g. HF). While a review of
the literature and an independent investigation of Rijken
et al. demonstrated that co-occurring diseases are associ-
ated, as expected, with worse scores on general health
status measures, they did not examine the inﬂuence of co-
occurring diseases on disease-speciﬁc instruments [29]. To
examine the relative performance of generic and disease-
speciﬁc instruments, Ren and colleagues demonstrated, in
both cross-sectional [30] and longitudinal [31] analyses,
that disease-speciﬁc measures outperformed generic mea-
sures in terms of their content and discriminative validity
among veterans with multiple comorbidities. However,
these latter studies did not focus upon the ability of a
disease-speciﬁc measure to be a psychometrically valid
representation of the disease of interest when another co-
occurring illness may manifest similar symptoms.
One research situation in which one disease has similar
symptoms to another is depression and heart failure.
Numerous studies have documented that depressed patients
have worse health status than nondepressed patients
[32–35], yet both depression and heart failure can manifest
symptoms of fatigue. Interestingly, Rumsfeld et al. were
able to demonstrate that depression was associated with
worse KCCQ scores over time, regardless of baseline
scores, and that among nondepressed patients, poorer
health status was associated with a greater likelihood of
becoming depressed [36]. These studies did not address
whether the KCCQ was equally valid in both depressed
and nondepressed patients, but did show important
interrelationships between diseases that can have similar
clinical manifestations.
Several potential limitations of this article should be
considered in interpreting our ﬁndings. First, validation is
always difﬁcult to establish given the absence of a criterion
standard for a patient-centered outcome such as health
status. We selected the NYHA classiﬁcation because it is a
commonly used metric with which to quantify HF patients’
health status. Yet the reproducibility and interobserver
variability of NYHA assessments is known to be lower
than directly soliciting such data from patients themselves.
[37]. A second concern is that our assessments of change in
HF came from a global patient-reported estimate of
change. At best this is a crude assessment and much more
detailed examinations of clinical change in the KCCQ have
been conducted [28]. Although the quantitative assess-
ments of change in KCCQ scores may be different than in
previous studies, there is no a priori reason to suspect that
these patient-reported assessments of global change would
differ by patients’ anemia status. Therefore, ﬁnding similar
associations between 3-month change in KCCQ scores and
patients’ global assessments of change between those with
and without anemia supports the fact that the responsive-
ness of the KCCQ to clinical change is similar in both
populations of patients. In addition, concluding that no
differences exist in the performance characteristics of the
KCCQ in anemic and nonanemic patients could be incor-
rect due to a type II error. However, the point estimates for
all of our analyses were extremely similar and included
more than 800 patients, which is greater than six times as
large as the original study documenting the reliability and
validity (including responsiveness) of the KCCQ [10].
Finally, 12% of patients were lost to follow-up and we
cannot exclude the introduction of a potential bias from
failing to include these patients. Supporting the generaliz-
ability of our study, however, is the similar degree of
association between KCCQ scores and NYHA classiﬁca-
tion, the similar estimates of internal consistency and test–
retest reliability, and similar responsiveness observed in
this population as seen in other studies testing the psy-
chometric properties of the KCCQ [10, 28].
In summary, we provide empirical evidence to support
the ability of a disease-speciﬁc measure of heart failure
patients’ health status, the KCCQ, regardless of the
presence of anemia. As such, we believe that patient-
reported health status outcomes are a valid, reliable, and
sensitive means to quantify the impact of anemia treat-
ment on HF-speciﬁc outcomes. Given that the
improvement in patients’ health status is a primary goal
of treatment, being able to accurately capture HF patients’
health status in trials of anemia therapy are important.
The KCCQ should be a valid and sensitive measure for
accomplishing these goals.
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